Xilio reports encouraging Phase 1 data for XTX101: partial response in PD-L1 neg NSCLC, favorable safety at RP2D

Xilio Therapeutics, Inc.

Preliminary data from Phase 1 trial of XTX101 in 25 patients with advanced solid tumors; RP2D set at 150 mg Q6W.
Partial response observed at nine weeks in a PD-L1 negative advanced NSCLC patient with hepatic metastases, continuing on treatment.
At RP2D, no Grade 4/5 treatment-related AEs, no colitis or infusion reactions; only Grade 3 AE was diarrhea (resolved).
Evidence of tumor-selective activation: low unmasked drug in peripheral circulation and minimal immune activation in periphery.
Plans to explore XTX101 in combination with PD-(L)1 in immunotherapy-resistant tumor types, including MSI-stable CRC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.